BRCA mutations in women confer a high risk for breast and ovarian cancers. The risks to male carriers are poorly understood and risk management strategies undescribed. This review summarizes current evidence and gives recommendations for counseling male BRCA mutation carriers. Reported risks for breast, prostate, pancreatic, gastric and hematologic cancers are higher in male BRCA mutation carri...

Mexican women with ovarian cancer have a high prevalence of germline BRCA mutations. The most frequent alteration is the deletion exons 9 to 12 BRCA1 (BRCA1-Del Exon 9-12), which has been associated founder effect in this population. mutation long genomic rearrangement that could affect not only clinical features but also prognosis patients carrying alteration. This retrospective study evaluate...

BACKGROUND Women with BRCA1 and BRCA2 mutation carriers are at substantially elevated risk of developing ovarian cancer. The aim of the meta-analysis is to clarify the role of risk-reducing salpingo-oophorectomy (RRSO) to reduce ovarian cancer risk and mortality in women with BRCA 1 and BRCA 2 mutation carriers. METHODS Pubmed, Medline and Scopus were searched to select English-language artic...

Women who have an inherited mutation in the BRCA1 or BRCA2 genes have a substantial increased lifetime risk of developing epithelial ovarian cancer (EOC), and epidemiological factors related to parity, ovulation, and hormone regulation have a dramatic effect on the risk in both BRCA mutation carriers and non-carriers. The most common and most aggressive histotype of EOC, high-grade serous carci...

Evidence shows that Black women diagnosed with breast cancer are substantially less likely to undergo BRCA testing and other multipanel genetic testing compared to White women, despite having a higher incidence of early-age onset breast cancer and triple-negative breast cancer (TNBC). Our study identifies predictors of BRCA testing among Black women treated for breast cancer and examines differ...

Breast cancer development in BRCA1/2 mutation carriers is a net consequence of cell-autonomous and cell nonautonomous factors which may serve as excellent targets for cancer prevention. In light of our previous data we sought to investigate the consequences of the BRCA-mutation carrier state on RANKL/osteoprotegerin (OPG) signalling. We analysed serum levels of RANKL, OPG, RANKL/OPG complex, oe...

1512 Background: The frequency of a BRCA mutation among women with ductal carcinoma in situ (DCIS) has not been well described. Consequently, patients with DCIS were not historically considered ideal candidates for genetic testing even in the presence of a family history of breast and ovarian cancer. Therefore, we examined the prevalence of BRCA1/2 mutations in women diagnosed with DCIS. METH...

1596 Background: Magnetic resonance imaging (MRI) is the preferred imaging modality for screening and diagnosis of breast cancer in BRCA-1and BRCA-2 mutation carriers. However, there is limited data on the radiographic features of BRCA1/2-positive breast cancers on MRI. This study evaluates the MRI characteristics of BRCA1/2 -related breast cancers. METHODS All female BRCA mutation carriers w...

BACKGROUND Soy intake is associated with a lower risk of breast cancer. However, it is unclear whether the same reduction in risk associated with high soy intake is also applicable to familial or genetic breast cancer. OBJECTIVE The aim of this study was to assess the dietary factors among carriers and noncarriers of BRCA mutations in the Korean Hereditary Breast Cancer Study (KOHBRA). DESI...

One in nine women will develop breast cancer in her lifetime (Canadian Cancer Society, 2007). Hereditary breast cancer accounts for only five to 10 per cent of all breast cancers. However, women carrying a single high-penetrance gene mutation have a 40% to 80% chance of developing breast cancer (Fackenthal & Olopade, 2007). Most of these breast cancers occur in women under the age of 50. The BR...